InterCure
InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. Based in Herzliya.
InterCure: net income sharply up (+47.3%), sales up (+13.1%), operating income sharply up (+59.5%).
- Net income sharply upFY 2025
Net income: ₪−36M, vs. ₪−68M a year earlier, i.e. +47.3%.
- Sales upFY 2025
Revenue: ₪270M, vs. ₪239M a year earlier, i.e. +13.1%.
- Operating income sharply upFY 2025
Operating income: ₪−27M, vs. ₪−67M a year earlier, i.e. +59.5%.
- Cash flow sharply upFY 2025
Operating cash flow: ₪17M, vs. ₪−67M a year earlier, i.e. +125.2%.
What the market pays, vs. the sector
This company's valuation multiples history is being built day by day from now on.
P/E calculated on net income (last fiscal year). Sector median: companies in the — group tracked here. Prices: Yahoo Finance; market cap cross-checked with the Tel Aviv Stock Exchange for Israeli stocks. These ratios describe a price, not a value: none of them says whether the share is expensive or cheap.
Follow earnings · WhatsApp group TA-125Details ▾
Every report from a TA-125 company, analyzed the same day: key figures and year-on-year change, analysis in brief, share price reaction. One daily summary during earnings season.
Join the TA-125 groupDetailed figures and history
Financial summary
| FY 2025 | FY 2024 | FY 2024 | |
|---|---|---|---|
| Total assets | 691 | 763 | 763 |
| Current assets | 317 | 392 | 392 |
| Non-current assets | 374 | 371 | 371 |
| Equity | 396 | 398 | 398 |
| of which minority interests | −0 | 1 | 1 |
| Current liabilities | 214 | 227 | 227 |
| Non-current liabilities | 80 | 138 | 138 |
| Revenue | 270 | 239 | 239 |
| Gross profit | 33 | 30 | 30 |
| Operating income | −27 | −67 | −67 |
| Pre-tax income | −44 | −87 | −87 |
| Net income | −37 | −73 | −73 |
| Net income (attributable to shareholders) | −36 | −68 | −68 |
| Dividends paid | 0 | 0 | 0 |
| Operating cash flow | 17 | −67 | −67 |
In millions of shekels. The "H1" columns cover the first six months of the year.
Calculated from these figures
| FY 2025 | FY 2024 | FY 2024 | |
|---|---|---|---|
| Gross margin | 12.3% | 12.7% | 12.7% |
| Operating margin | −10.1% | −28.1% | −28.1% |
| Net margin | −13.2% | −28.4% | −28.4% |
| Current ratio (current assets / current liabilities) | 1,5 x | 1,7 x | 1,7 x |
| Equity / total assets | 57.4% | 52.1% | 52.1% |
The 5-year history, charts and cross-check models are coming for companies listed only in Tel Aviv: each new filing on Maya is kept and enriches the page.
Company overview
InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in the biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.
Source: official company profile (Yahoo Finance), summary. Website: www.intercure.co
- Maya, Tel Aviv Stock Exchange: company page and reports
No dividend paid over the past five years (source: Yahoo Finance).